Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
#UCB is using next-generation technology to pioneer a completely new approach to #clinicalstudydesign – the End to End Clinical Study Automation program will mean quicker #clinicalstudyresults and faster delivery of new clinical options for patients. http
— UCB News (@ucb_news) 05.03.2021 -
UCB’s ambition is to transform the lives of people living with severe diseases by developing personalized experiences. We believe that #digitaltransformation will help drive our vision forward. #digitalbusinesstransformation https://t.co/mN05l4nXQC https
— UCB News (@ucb_news) 05.03.2021 -
Click to visit the #AdvantageHers resource hub to read @CaroWoznaicki top tips for creating a chronic inflammatory disease game plan: https://t.co/kKwruXQRXx https://t.co/HbjffY5ujC
— UCB News (@ucb_news) 04.03.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
